Chromocell renamed Channel Therapeutics, reincorporates in Nevada; pipeline milestones expected soon

Pelthos Therapeutics Inc.

Name change to Channel Therapeutics effective Nov 18, 2024; reincorporation in Nevada for lower taxes and strategic flexibility.
Depot program for postoperative nerve blocks: sustained drug release over 96 hours in animals; efficacy results imminent.
Eye pain program: drops well tolerated in animals; efficacy results in weeks, toxicology data late Q1 2025, Phase II in Q2 2025.
Chronic pain program exploring program-specific financing; kickoff expected in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.